istock-955926616_baona
baona / iStockphoto.com
2 October 2018AsiaNeeti Wilson, Arpita Kulshreshtha and Gitika Suri

A patent attack on three fronts

The Indian patent system has been known for its strict prosecution of patents in the pharmaceutical sector ever since the product patent regime came into force in 2005. Furthermore, several opportunities are provided to third parties to challenge patent applications and make use of multiple pre-grant oppositions, while post-grant attacks are the norm for important pharma product patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
Asia
4 December 2025   The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
Asia
7 November 2025   Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.